Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ERIC P TAMM and MATTHEW HAROLD KATZ.
ERIC P TAMM
Connection Strength
1.668
MATTHEW HAROLD KATZ
  1. CT features predictive of nodal positivity at surgery in pancreatic cancer patients following neoadjuvant therapy in the setting of dual energy CT. Abdom Radiol (NY). 2021 06; 46(6):2620-2627.
    View in: PubMed
    Score: 0.191
  2. Analysis of free-form radiology dictations for completeness and clarity for pancreatic cancer staging. Abdom Imaging. 2015 Oct; 40(7):2391-7.
    View in: PubMed
    Score: 0.133
  3. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg. 2012 Aug; 215(2):e11-8.
    View in: PubMed
    Score: 0.106
  4. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.105
  5. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am. 2012 May; 50(3):407-28.
    View in: PubMed
    Score: 0.104
  6. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.090
  7. Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach. J Am Coll Surg. 2008 Jul; 207(1):106-20.
    View in: PubMed
    Score: 0.079
  8. New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study. Endosc Ultrasound. 2024 Mar-Apr; 13(2):83-88.
    View in: PubMed
    Score: 0.060
  9. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.053
  10. Baseline CT-based Radiomic Features Aid Prediction of Nodal Positivity after Neoadjuvant Therapy in Pancreatic Cancer. Radiol Imaging Cancer. 2022 03; 4(2):e210068.
    View in: PubMed
    Score: 0.052
  11. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69.
    View in: PubMed
    Score: 0.051
  12. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer. 2022 Jan 03; 22(1):14.
    View in: PubMed
    Score: 0.051
  13. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Cancers (Basel). 2020 Dec 05; 12(12).
    View in: PubMed
    Score: 0.047
  14. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021 Jan; 21(1):200-207.
    View in: PubMed
    Score: 0.047
  15. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. 2020 Jan-Feb; 9(1):24-30.
    View in: PubMed
    Score: 0.044
  16. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.043
  17. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE. 2019 May; 4(5):223-225.
    View in: PubMed
    Score: 0.042
  18. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
    View in: PubMed
    Score: 0.041
  19. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894.
    View in: PubMed
    Score: 0.040
  20. Significance of T1a and T1b Carcinoma Arising in Mucinous Cystic Neoplasm of Pancreas. Am J Surg Pathol. 2018 05; 42(5):578-586.
    View in: PubMed
    Score: 0.040
  21. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.039
  22. Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget. 2016 Dec 27; 7(52):85776-85784.
    View in: PubMed
    Score: 0.036
  23. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
    View in: PubMed
    Score: 0.036
  24. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
    View in: PubMed
    Score: 0.031
  25. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.030
  26. Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdom Imaging. 2013 Apr; 38(2):342-57.
    View in: PubMed
    Score: 0.028
  27. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2012 Sep; 199(3):602-8.
    View in: PubMed
    Score: 0.027
  28. Current diagnosis and management of unusual pancreatic tumors. Am J Surg. 2008 Jul; 196(1):100-13.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.